ORTHO MICRONOR- norethindrone tablet
Janssen Pharmaceuticals, Inc.
----------
Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
ORTHO MICRONOR® progestin-only oral contraceptives prevent conception by suppressing ovulation in approximately half of users, thickening the cervical mucus to inhibit sperm penetration, lowering the midcycle LH and FSH peaks, slowing the movement of the ovum through the fallopian tubes, and altering the endometrium.
Serum progestin levels peak about two hours after oral administration, followed by rapid distribution and elimination. By 24 hours after drug ingestion, serum levels are near baseline, making efficacy dependent upon rigid adherence to the dosing schedule. There are large variations in serum levels among individual users. Progestin-only administration results in lower steady-state serum progestin levels and a shorter elimination half-life than concomitant administration with estrogens.
If used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. However, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. Table 1 lists the pregnancy rates for users of all major methods of contraception.
% of Women Experiencing an Unintended Pregnancy within the First Year of Use | % of Women Continuing Use at One Year* | ||
---|---|---|---|
Method (1) | Typical Use†
(2) | Perfect Use‡
(3) | (4) |
Emergency Contraception: Emergency contraceptive pills or insertion of a copper intrauterine contraceptive after unprotected intercourse substantially reduces the risk of pregnancy.§ (See Chapter 6.). | |||
Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception.¶ (See Chapter 18.) | |||
Source: Trussell J. Contraceptive Efficacy. In Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M. Contraceptive Techology: Twentieth Revised Edition. New York NY: Ardent Media, 2011. | |||
Notes: | |||
|
|||
No method# | 85 | 85 | |
SpermicidesÞ | 28 | 18 | 42 |
Fertility awareness-based methods | 24 | 47 | |
Standard Days methodß | 5 | ||
TwoDay methodß | 4 | ||
Ovulation methodß | 3 | ||
Symptothermal methodß | 0.4 | ||
Withdrawal | 22 | 4 | 46 |
Sponge | 36 | ||
Parous women | 24 | 20 | |
Nulliparous women | 12 | 9 | |
Condomà | |||
Female (fc) | 21 | 5 | 41 |
Male | 18 | 2 | 43 |
Diaphragmè | 12 | 6 | 57 |
Combined pill and progestin-only pill | 9 | 0.3 | 67 |
Norelgestromin and ethinyl estradiol patch | 9 | 0.3 | 67 |
NuvaRing | 9 | 0.3 | 67 |
Depo-Provera | 6 | 0.2 | 56 |
Intrauterine contraceptives | |||
ParaGard (copper T) | 0.8 | 0.6 | 78 |
Mirena (LNg) | 0.2 | 0.2 | 80 |
Implanon | 0.05 | 0.05 | 84 |
Female sterilization | 0.5 | 0.5 | 100 |
Male sterilization | 0.15 | 0.10 | 100 |
ORTHO MICRONOR® Tablets have not been studied for and are not indicated for use in emergency contraception.
Progestin-only oral contraceptives (POPs) should not be used by women who currently have the following conditions:
Cigarette smoking increases the risk of serious cardiovascular disease. Women who use oral contraceptives should be strongly advised not to smoke.
ORTHO MICRONOR® does not contain estrogen and, therefore, this insert does not discuss the serious health risks that have been associated with the estrogen component of combined oral contraceptives (COCs). The healthcare professional is referred to the prescribing information of combined oral contraceptives for a discussion of those risks. The relationship between progestin-only oral contraceptives and these risks is not fully defined. The healthcare professional should remain alert to the earliest manifestation of symptoms of any serious disease and discontinue oral contraceptive therapy when appropriate.
The incidence of ectopic pregnancies for progestin-only oral contraceptive users is 5 per 1000 woman-years. Up to 10% of pregnancies reported in clinical studies of progestin-only oral contraceptive users are extrauterine. Although symptoms of ectopic pregnancy should be watched for, a history of ectopic pregnancy need not be considered a contraindication to use of this contraceptive method. Healthcare professionals should be alert to the possibility of an ectopic pregnancy in women who become pregnant or complain of lower abdominal pain while on progestin-only oral contraceptives.
If follicular development occurs, atresia of the follicle is sometimes delayed and the follicle may continue to grow beyond the size it would attain in a normal cycle. Generally these enlarged follicles disappear spontaneously. Often they are asymptomatic; in some cases they are associated with mild abdominal pain. Rarely they may twist or rupture, requiring surgical intervention.
Irregular menstrual patterns are common among women using progestin-only oral contraceptives. If genital bleeding is suggestive of infection, malignancy or other abnormal conditions, such nonpharmacologic causes should be ruled out. If prolonged amenorrhea occurs, the possibility of pregnancy should be evaluated.
Some epidemiological studies of oral contraceptive users have reported an increased relative risk of developing breast cancer, particularly at a younger age and apparently related to duration of use. These studies have predominantly involved combined oral contraceptives and there is insufficient data to determine whether the use of POPs similarly increases the risk.
A meta-analysis of 54 studies found a small increase in the frequency of having breast cancer diagnosed for women who were currently using combined oral contraceptives or had used them within the past ten years.
This increase in the frequency of breast cancer diagnosis, within ten years of stopping use, was generally accounted for by cancers localized to the breast. There was no increase in the frequency of having breast cancer diagnosed ten or more years after cessation of use.
Women with breast cancer should not use oral contraceptives because the role of female hormones in breast cancer has not been fully determined.
Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia in some populations of women. However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors. There is insufficient data to determine whether the use of POPs increases the risk of developing cervical intraepithelial neoplasia.
Benign hepatic adenomas are associated with combined oral contraceptive use, although the incidence of benign tumors is rare in the United States. Rupture of benign, hepatic adenomas may cause death through intra-abdominal hemorrhage.
Studies have shown an increased risk of developing hepatocellular carcinoma in combined oral contraceptive users. However, these cancers are rare in the U.S. There is insufficient data to determine whether POPs increase the risk of developing hepatic neoplasia.
Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
It is considered good medical practice for sexually active women using oral contraceptives to have annual history and physical examinations. The physical examination may be deferred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the healthcare professional.
Some users may experience slight deterioration in glucose tolerance, with increases in plasma insulin but women with diabetes mellitus who use progestin-only oral contraceptives do not generally experience changes in their insulin requirements. Nonetheless, prediabetic and diabetic women in particular should be carefully monitored while taking POPs.
Lipid metabolism is occasionally affected in that HDL, HDL2, and apolipoprotein A-I and A-II may be decreased; hepatic lipase may be increased. There is usually no effect on total cholesterol, HDL3, LDL, or VLDL.
Consult the labeling of concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations.
Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the systemic concentrations of HCs and potentially diminish the effectiveness of HCs or increase breakthrough bleeding.
Some drugs or herbal products that may decrease the effectiveness of HCs include efavirenz, phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. Interactions between HCs and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative non-hormonal method of contraception or a back-up method when enzyme inducers are used with HCs, and to continue back-up non-hormonal contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability.
Co-administration of certain HCs and strong or moderate CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase the systemic concentrations of progestins, including norethindrone.
Significant decreases in systemic concentrations of progestin have been noted in cases of co-administration with some HIV protease inhibitors (e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir), some HCV protease inhibitors (e.g., boceprevir and telaprevir), and some non-nucleoside reverse transcriptase inhibitors (e.g., nevirapine, efavirenz).
In contrast, significant increases in systemic exposure of the progestin have been noted in cases of co-administration with certain other HIV protease inhibitors (e.g., indinavir and atazanavir/ritonavir) and with other non-nucleoside reverse transcriptase inhibitors (e.g., etravirine).
These changes may be clinically relevant in some cases.
Consult the prescribing information of anti-viral and anti-retroviral concomitant medications to identify potential interactions.
Hormonal contraceptives may affect the metabolism of other drugs. Consequently, systemic concentrations may either increase (for example, cyclosporine) or decrease. Consult the labeling of all concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations.
Effectiveness of progestin-containing hormonal contraceptives and emergency contraceptive ulipristal acetate may be decreased if progestin-containing hormonal contraceptives are used within five days after ulipristal acetate dosing. Therefore, if a woman wishes to use ORTHO MICRONOR® after using ulipristal acetate, she should do so no sooner than 5 days after the intake of ulipristal acetate and she should use a reliable barrier method for subsequent acts of intercourse until her next menstrual period.
The following endocrine tests may be affected by progestin-only oral contraceptive use:
Many studies have found no effects on fetal development associated with long-term use of contraceptive doses of oral progestins. The few studies of infant growth and development that have been conducted have not demonstrated significant adverse effects. It is nonetheless prudent to rule out suspected pregnancy before initiating any hormonal contraceptive use.
In general, no adverse effects have been found on breastfeeding performance or on the health, growth, or development of the infant. However, isolated post-marketing cases of decreased milk production have been reported. Small amounts of progestins pass into the breast milk of nursing mothers, resulting in detectable steroid levels in infant plasma.
Safety and efficacy of ORTHO MICRONOR® Tablets have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before menarche is not indicated.
The limited available data indicate a rapid return of normal ovulation and fertility following discontinuation of progestin-only oral contraceptives.
The onset or exacerbation of migraine or development of severe headache with focal neurological symptoms which is recurrent or persistent requires discontinuation of progestin-only contraceptives and evaluation of the cause.
1. See "Detailed Patient Labeling" for detailed information.
2. Counseling issues
The following points should be discussed with prospective users before prescribing progestin-only oral contraceptives:
Adverse reactions reported with the use of POPs include:
The following adverse reactions were also reported in clinical trials or during post-marketing experience: Gastrointestinal Disorders: vomiting, abdominal pain; General Disorders and Administration Site Conditions: fatigue, edema; Psychiatric Disorders: depression, nervousness; Musculoskeletal and Connective Tissue Disorders: pain in extremity; Reproductive System and Breast Disorders: genital discharge; breast pain, menstruation delayed, suppressed lactation, vaginal hemorrhage, menorrhagia, withdrawal bleed when product is stopped; Immune System Disorders: anaphylactic/anaphylactoid reaction, hypersensitivity; Hepatobiliary Disorders: hepatitis, jaundice cholestatic; Skin and Subcutaneous Tissue Disorders: alopecia, rash, rash pruritic.
There have been no reports of serious ill effects from overdosage, including ingestion by children.
To achieve maximum contraceptive effectiveness, ORTHO MICRONOR® must be taken exactly as directed. One tablet is taken every day, at the same time. Administration is continuous, with no interruption between pill packs. See Detailed Patient Labeling for detailed instruction.
ORTHO MICRONOR® (0.35 mg norethindrone) Tablets are available in a single pouch containing a VERIDATE® blister card (refill) of 28 tablets (NDC 50458-194-28). The blister card contains 28 lime green, round, flat faced, beveled edge tablets, imprinted "ORTHO 0.35" on both sides. ORTHO MICRONOR® Tablets are packaged in a carton containing 6 pouches and 6 unfilled VERIDATE® Tablet Dispensers (NDC 50458-194-06).
ORTHO MICRONOR® (0.35 mg norethindrone) Tablets are also available for clinic usage in a VERIDATE® Tablet Dispenser (unfilled) and VERIDATE® refills (NDC 50458-194-23 and NDC 50458-194-12).
ORTHO MICRONOR® (0.35 mg norethindrone) Tablets are available in a DIALPAK® Tablet Dispenser (unfilled) and DIALPAK® refills (NDC 50458-194-00 and NDC 50458-194-16).
This product (like all oral contraceptives) is used to prevent pregnancy. It does not protect against HIV infection (AIDS) or other sexually transmitted diseases.
DESCRIPTION
ORTHO MICRONOR® Tablets
Each tablet contains 0.35 mg norethindrone. Inactive ingredients include D&C Green No. 5, D&C Yellow No. 10, lactose, magnesium stearate, modified corn starch, and povidone.
INTRODUCTION
This leaflet is about birth control pills that contain one hormone, a progestin. Please read this leaflet before you begin to take your pills. It is meant to be used along with talking with your healthcare professional.
Progestin-only pills are often called "POPs" or "the minipill." POPs have less progestin than the combined birth control pill (or "the pill") which contains both an estrogen and a progestin.
HOW EFFECTIVE ARE POPs?
About 1 in 200 POP users will get pregnant in the first year if they all take POPs perfectly (that is, on time, every day). About 1 in 20 "typical" POP users (including women who are late taking pills or miss pills) gets pregnant in the first year of use. Table 2 will help you compare the efficacy of different methods.
% of Women Experiencing an Unintended Pregnancy within the First Year of Use | % of Women Continuing Use at One Year* | ||
---|---|---|---|
Method (1) | Typical Use†
(2) | Perfect Use‡
(3) | (4) |
Emergency Contraception: Emergency contraceptive pills or insertion of a copper intrauterine contraceptive after unprotected intercourse substantially reduces the risk of pregnancy.§ (See Chapter 6.). | |||
Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception.¶ (See Chapter 18.) | |||
Source: Trussell J. Contraceptive Efficacy. In Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M. Contraceptive Techology: Twentieth Revised Edition. New York NY: Ardent Media, 2011. | |||
Notes: | |||
|
|||
No method# | 85 | 85 | |
SpermicidesÞ | 28 | 18 | 42 |
Fertility awareness-based methods | 24 | 47 | |
Standard Days methodß | 5 | ||
TwoDay methodß | 4 | ||
Ovulation methodß | 3 | ||
Symptothermal methodß | 0.4 | ||
Withdrawal | 22 | 4 | 46 |
Sponge | 36 | ||
Parous women | 24 | 20 | |
Nulliparous women | 12 | 9 | |
Condomà | |||
Female (fc) | 21 | 5 | 41 |
Male | 18 | 2 | 43 |
Diaphragmè | 12 | 6 | 57 |
Combined pill and progestin-only pill | 9 | 0.3 | 67 |
norelgestromin and ethinyl estradiol patch | 9 | 0.3 | 67 |
NuvaRing | 9 | 0.3 | 67 |
Depo-Provera | 6 | 0.2 | 56 |
Intrauterine contraceptives | |||
ParaGard (copper T) | 0.8 | 0.6 | 78 |
Mirena (LNg) | 0.2 | 0.2 | 80 |
Implanon | 0.05 | 0.05 | 84 |
Female sterilization | 0.5 | 0.5 | 100 |
Male sterilization | 0.15 | 0.10 | 100 |
ORTHO MICRONOR® Tablets have not been studied for and are not indicated for use in emergency contraception.
HOW DO POPs WORK?
POPs can prevent pregnancy in different ways including:
YOU SHOULD NOT TAKE POPs
RISKS OF TAKING POPs
Cigarette smoking greatly increases the possibility of suffering heart attacks and strokes. Women who use oral contraceptives are strongly advised not to smoke.
WARNING:
If you have sudden or severe pain in your lower abdomen or stomach area, you may have an ectopic pregnancy or an ovarian cyst. If this happens, you should contact your healthcare professional immediately.
Ectopic Pregnancy
An ectopic pregnancy is a pregnancy outside the womb. Because POPs protect against pregnancy, the chance of having a pregnancy outside the womb is very low. If you do get pregnant while taking POPs, you have a slightly higher chance that the pregnancy will be ectopic than do users of some other birth control methods.
Ovarian Cysts
These cysts are small sacs of fluid in the ovary. They are more common among POP users than among users of most other birth control methods. They usually disappear without treatment and rarely cause problems.
Cancer of the Reproductive Organs and Breasts
Some studies in women who use combined oral contraceptives that contain both estrogen and a progestin have reported an increase in the risk of developing breast cancer, particularly at a younger age and apparently related to duration of use. There is insufficient data to determine whether the use of POPs similarly increases this risk.
A meta-analysis of 54 studies found a small increase in the frequency of having breast cancer diagnosed for women who were currently using combined oral contraceptives or had used them within the past ten years. This increase in the frequency of breast cancer diagnosis, within ten years of stopping use, was generally accounted for by cancers localized to the breast. There was no increase in the frequency of having breast cancer diagnosed ten or more years after cessation of use.
Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives and there is insufficient data to determine whether the use of POPs increases the risk of developing cancer of the cervix.
Liver Tumors
In rare cases, combined oral contraceptives can cause benign but dangerous liver tumors. These benign liver tumors can rupture and cause fatal internal bleeding. In addition, some studies report an increased risk of developing liver cancer among women who use combined oral contraceptives. However, liver cancers are rare. There is insufficient data to determine whether POPs increase the risk of liver tumors.
Diabetic Women
Diabetic women taking POPs do not generally require changes in the amount of insulin they are taking. However, your healthcare professional may monitor you more closely under these conditions.
SEXUALLY TRANSMITTED DISEASES (STDs)
WARNING: POPs do not protect against getting or giving someone HIV (AIDS) or any other STD, such as chlamydia, gonorrhea, genital warts or herpes.
SIDE EFFECTS
Irregular Bleeding:
The most common side effect of POPs is a change in menstrual bleeding. Your periods may be either early or late, and you may have some spotting between periods. Taking pills late or missing pills can result in some spotting or bleeding.
Other Side Effects:
Less common side effects include headaches, tender breasts, nausea, vomiting, dizziness, and fatigue. Depression, nervousness, leg pain, vaginal discharge, fluid retention, allergic reactions, jaundice or a yellowing of the skin or eyeballs, loss of scalp hair, rash/itchy rash, weight gain, acne and extra hair on your face and body have been reported, but are rare.
If you are concerned about any of these side effects, check with your healthcare professional.
USING POPs WITH OTHER MEDICINES
Before taking a POP, inform your healthcare professional of any other medication, including over-the-counter medicine, that you may be taking.
These medicines can make POPs less effective:
Medicines for seizures such as:
Medicine for nausea and vomiting caused by certain anti-cancer (chemotherapy) medicines:
Medicines for tuberculosis (TB):
Medicine for fungal infections such as:
Medicine for pulmonary hypertension such as:
Medicines used for the treatment of HIV infections or AIDS and infections due to Hepatitis C such as:
Herbal products such as:
These medicines and substances can increase your exposure to POPs:
Grapefruit juice
Medicines for fungal infections such as:
Before you begin taking any new medicines be sure your healthcare professional knows you are taking a progestin-only birth control pill.
HOW TO TAKE POPs
IMPORTANT POINTS TO REMEMBER |
STARTING POPs |
IF YOU ARE LATE OR MISS TAKING YOUR POPs |
IF YOU ARE BREASTFEEDING |
IF YOU ARE SWITCHING PILLS |
PREGNANCY WHILE ON THE PILL
If you think you are pregnant, contact your healthcare professional. Even though research has shown that POPs do not cause harm to the unborn baby, it is always best not to take any drugs or medicines that you don't need when you are pregnant.
You should get a pregnancy test:
WILL POPs AFFECT YOUR ABILITY TO GET PREGNANT LATER?
If you want to become pregnant, simply stop taking POPs. POPs will not delay your ability to get pregnant.
BREASTFEEDING
If you are breastfeeding, POPs will not affect the quality or amount of your breast milk or the health of your nursing baby. However, isolated cases of decreased milk production have been reported.
OVERDOSE
No serious problems have been reported when many pills were taken by accident, even by a small child, so there is usually no reason to treat an overdose.
OTHER QUESTIONS OR CONCERNS
If you have any questions or concerns, check with your healthcare professional. You can also ask for the more detailed "Professional Labeling" written for doctors and other healthcare professionals.
HOW TO STORE YOUR POPs
Store at 25°C (77°F); excursions permitted to 15°–30°C (59°–86°F).
Keep out of reach of children.
INSTRUCTIONS FOR USING YOUR ORTHO DIALPAK® TABLET DISPENSER |
|||
Please Read Me! | |||
Save these Instructions. | |||
|
|
|
|
| SET THE DAY:
□ Day 1 Start: turn the dial on your empty ORTHO DIALPAK until the arrow points to the first day of your period (if your period starts on Tuesday, the arrow will point to TU). □ If you decide to take your first POP on another day, use a backup method (such as a condom and/or a spermicide) every time you have sex during the next 48 hours. | Insert the new refill by lining up the "V" shape on the refill with the "V" shape at the top of your ORTHO DIALPAK. Snap the refill in place. You are ready to take pill "1." You should always begin your pill cycle with pill "1," as shown on the inner part of the refill ring. | Remove pill "1" by pushing down on the pill. The pill will come out through a hole in the back of the ORTHO DIALPAK. |
|
|
|
|
Swallow the pill. You will take one pill each day. POPs must be taken at the same time every day, so choose a time and then take the pill at that same time every day. Every time you take a pill late, and especially if you miss a pill, you are more likely to get pregnant. | Wait 24 hours to take your next pill. POPs must be taken at the same time every day, so choose a time and then take the pill at that same time every day. Every time you take a pill late, and especially if you miss a pill, you are more likely to get pregnant. To take pill "2," turn the dial on your ORTHO DIALPAK to the next day. Continue to take one pill each day whether bleeding or not until all the pills have been taken. | Take your pill at the same time every day. It is important to take the correct pill each day and not miss any pills. To help you remember, take your pill at the same time as another daily activity, like turning off your alarm clock or brushing your teeth. | When your refill is empty, keep your ORTHO DIALPAK case.
You will start a new refill on the day after pill "28." |
| |||
Turn the dial to the pill "1" position to remove the empty refill and insert a new refill. THE FIRST PILL IN EVERY REFILL WILL ALWAYS BE TAKEN ON THE SAME DAY OF THE WEEK, NO MATTER WHEN YOUR NEXT PERIOD STARTS. |
If you are late or you miss taking your POPs:
Important points to remember:
INSTRUCTIONS FOR USE VERIDATE® Tablet Dispenser-28's |
1. Place the refill in the VERIDATE® so that the V notch in the refill is at the top of the dispenser (see drawing). Press the refill down so that it fits firmly under all nibs.
2. The first time you use these pills, take your first pill on the first day of your menstrual period.
3. Choose a pill that corresponds with the day of the week on which you are taking the first pill.
4. Continue taking one pill daily, clockwise, until no pills remain in the outer circle. It is important that you take your pills at the same time every day.
5. The next day, take a pill from the inner circle that corresponds with the day of the week it happens to be. Take a pill each day until all seven are taken.
6. After you have taken all 28 pills, insert a new refill in the VERIDATE® and begin taking your pills again the next day. Be sure the calendar day on the package corresponds with the actual day.
Mfd. by:
Janssen Ortho LLC
Manati, Puerto Rico 00674
Mfd. for:
Janssen Pharmaceuticals, Inc.
Titusville, New Jersey 08560
© 2001 Janssen Pharmaceutical Companies
Revised November 2021
NDC 50458-194-06
28-DAY
REGIMEN
Same Product
New Look
ORTHO
MICRONOR®
(norethindrone) TABLETS
0.35 mg
Each lime green tablet contains 0.35 mg norethindrone.
Contains: 6 Veridate® Tablet Dispensers and 6 Refills, 28 Tablets Each
This product (like all oral contraceptives) is intended to
prevent pregnancy. It does not protect against HIV infection
(AIDS) and other sexually transmitted diseases.
Rx only
janssen
ORTHO MICRONOR
norethindrone tablet |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Labeler - Janssen Pharmaceuticals, Inc. (063137772) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
Janssen Ortho, LLC | 084894661 | MANUFACTURE(50458-194) , ANALYSIS(50458-194) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
Ortho Biologics, LLC | 606111821 | ANALYSIS(50458-194) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
Janssen Pharmaceuticals, Inc. | 063137772 | ANALYSIS(50458-194) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
Aspen Oss B.V. | 491013870 | API MANUFACTURE(50458-194) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
Aspen Oss B.V. | 491017488 | API MANUFACTURE(50458-194) |